Cargando…
Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa
Omicron lineages BA.4 and BA.5 drove a fifth wave of COVID-19 cases in South Africa. Here, we use the presence/absence of the S-gene target as a proxy for SARS-CoV-2 variant/lineage for infections diagnosed using the TaqPath PCR assay between 1 October 2021 and 26 April 2022. We link national COVID-...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531215/ https://www.ncbi.nlm.nih.gov/pubmed/36195617 http://dx.doi.org/10.1038/s41467-022-33614-0 |
| _version_ | 1784801855427051520 |
|---|---|
| author | Wolter, Nicole Jassat, Waasila Walaza, Sibongile Welch, Richard Moultrie, Harry Groome, Michelle J. Amoako, Daniel Gyamfi Everatt, Josie Bhiman, Jinal N. Scheepers, Cathrine Tebeila, Naume Chiwandire, Nicola du Plessis, Mignon Govender, Nevashan Ismail, Arshad Glass, Allison Mlisana, Koleka Stevens, Wendy Treurnicht, Florette K. Subramoney, Kathleen Makatini, Zinhle Hsiao, Nei-yuan Parboosing, Raveen Wadula, Jeannette Hussey, Hannah Davies, Mary-Ann Boulle, Andrew von Gottberg, Anne Cohen, Cheryl |
| author_facet | Wolter, Nicole Jassat, Waasila Walaza, Sibongile Welch, Richard Moultrie, Harry Groome, Michelle J. Amoako, Daniel Gyamfi Everatt, Josie Bhiman, Jinal N. Scheepers, Cathrine Tebeila, Naume Chiwandire, Nicola du Plessis, Mignon Govender, Nevashan Ismail, Arshad Glass, Allison Mlisana, Koleka Stevens, Wendy Treurnicht, Florette K. Subramoney, Kathleen Makatini, Zinhle Hsiao, Nei-yuan Parboosing, Raveen Wadula, Jeannette Hussey, Hannah Davies, Mary-Ann Boulle, Andrew von Gottberg, Anne Cohen, Cheryl |
| author_sort | Wolter, Nicole |
| collection | PubMed |
| description | Omicron lineages BA.4 and BA.5 drove a fifth wave of COVID-19 cases in South Africa. Here, we use the presence/absence of the S-gene target as a proxy for SARS-CoV-2 variant/lineage for infections diagnosed using the TaqPath PCR assay between 1 October 2021 and 26 April 2022. We link national COVID-19 individual-level data including case, laboratory test and hospitalisation data. We assess severity using multivariable logistic regression comparing the risk of hospitalisation and risk of severe disease, once hospitalised, for Delta, BA.1, BA.2 and BA.4/BA.5 infections. After controlling for factors associated with hospitalisation and severe outcome respectively, BA.4/BA.5-infected individuals had a similar odds of hospitalisation (aOR 1.24, 95% CI 0.98–1.55) and severe outcome (aOR 0.72, 95% CI 0.41–1.26) compared to BA.1-infected individuals. Newly emerged Omicron lineages BA.4/BA.5 showed similar severity to the BA.1 lineage and continued to show reduced clinical severity compared to the Delta variant. |
| format | Online Article Text |
| id | pubmed-9531215 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95312152022-10-04 Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa Wolter, Nicole Jassat, Waasila Walaza, Sibongile Welch, Richard Moultrie, Harry Groome, Michelle J. Amoako, Daniel Gyamfi Everatt, Josie Bhiman, Jinal N. Scheepers, Cathrine Tebeila, Naume Chiwandire, Nicola du Plessis, Mignon Govender, Nevashan Ismail, Arshad Glass, Allison Mlisana, Koleka Stevens, Wendy Treurnicht, Florette K. Subramoney, Kathleen Makatini, Zinhle Hsiao, Nei-yuan Parboosing, Raveen Wadula, Jeannette Hussey, Hannah Davies, Mary-Ann Boulle, Andrew von Gottberg, Anne Cohen, Cheryl Nat Commun Article Omicron lineages BA.4 and BA.5 drove a fifth wave of COVID-19 cases in South Africa. Here, we use the presence/absence of the S-gene target as a proxy for SARS-CoV-2 variant/lineage for infections diagnosed using the TaqPath PCR assay between 1 October 2021 and 26 April 2022. We link national COVID-19 individual-level data including case, laboratory test and hospitalisation data. We assess severity using multivariable logistic regression comparing the risk of hospitalisation and risk of severe disease, once hospitalised, for Delta, BA.1, BA.2 and BA.4/BA.5 infections. After controlling for factors associated with hospitalisation and severe outcome respectively, BA.4/BA.5-infected individuals had a similar odds of hospitalisation (aOR 1.24, 95% CI 0.98–1.55) and severe outcome (aOR 0.72, 95% CI 0.41–1.26) compared to BA.1-infected individuals. Newly emerged Omicron lineages BA.4/BA.5 showed similar severity to the BA.1 lineage and continued to show reduced clinical severity compared to the Delta variant. Nature Publishing Group UK 2022-10-04 /pmc/articles/PMC9531215/ /pubmed/36195617 http://dx.doi.org/10.1038/s41467-022-33614-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Article Wolter, Nicole Jassat, Waasila Walaza, Sibongile Welch, Richard Moultrie, Harry Groome, Michelle J. Amoako, Daniel Gyamfi Everatt, Josie Bhiman, Jinal N. Scheepers, Cathrine Tebeila, Naume Chiwandire, Nicola du Plessis, Mignon Govender, Nevashan Ismail, Arshad Glass, Allison Mlisana, Koleka Stevens, Wendy Treurnicht, Florette K. Subramoney, Kathleen Makatini, Zinhle Hsiao, Nei-yuan Parboosing, Raveen Wadula, Jeannette Hussey, Hannah Davies, Mary-Ann Boulle, Andrew von Gottberg, Anne Cohen, Cheryl Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa |
| title | Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa |
| title_full | Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa |
| title_fullStr | Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa |
| title_full_unstemmed | Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa |
| title_short | Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa |
| title_sort | clinical severity of sars-cov-2 omicron ba.4 and ba.5 lineages compared to ba.1 and delta in south africa |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531215/ https://www.ncbi.nlm.nih.gov/pubmed/36195617 http://dx.doi.org/10.1038/s41467-022-33614-0 |
| work_keys_str_mv | AT wolternicole clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica AT jassatwaasila clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica AT walazasibongile clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica AT welchrichard clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica AT moultrieharry clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica AT groomemichellej clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica AT amoakodanielgyamfi clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica AT everattjosie clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica AT bhimanjinaln clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica AT scheeperscathrine clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica AT tebeilanaume clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica AT chiwandirenicola clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica AT duplessismignon clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica AT govendernevashan clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica AT ismailarshad clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica AT glassallison clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica AT mlisanakoleka clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica AT stevenswendy clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica AT treurnichtflorettek clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica AT subramoneykathleen clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica AT makatinizinhle clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica AT hsiaoneiyuan clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica AT parboosingraveen clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica AT wadulajeannette clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica AT husseyhannah clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica AT daviesmaryann clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica AT boulleandrew clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica AT vongottberganne clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica AT cohencheryl clinicalseverityofsarscov2omicronba4andba5lineagescomparedtoba1anddeltainsouthafrica |